The new score means Waltham, Mass.-based Repligen is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. Repligen develops bioprocessing products for life sciences companies. Its stock was up 0.9% at 200.56 Friday afternoon despite the slumping overall market. It’s up about 155% from a coronavirus crash low of 78.41 on March 23, 2020.
Repligen Has Best Possible EPS Rating
The IBD Composite Rating helps investors easily measure the quality of a stock’s fundamental and technical metrics. The best growth stocks have a Composite Rating of 90 or better.
Additionally, the stock earns a 99 EPS Rating, which means its recent quarterly and annual earnings growth tops 99% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
In Q1, the company posted 113% EPS growth to 68 cents. Revenue jumped 88% to $142.8 million, up from 56% growth the prior quarter. That marks three consecutive reports with increasing revenue and EPS gains.
Repligen earns the No. 3 rank among its peers in the Medical-Products industry group. Align Technology (ALGN) is the No. 1-ranked stock within the group.
Repligen is currently forming a double-bottom base, with a 223.13 buy point. Look for the stock to break out in heavy trade at least 40% above average.
YOU MIGHT ALSO LIKE: